Diabetic Macular Edema

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the utility of a novel port delivery system for the delivery of anti-VEGF treatment.

Thought leaders review the clinical and practical implications of a novel port delivery system for the treatment of neovascular age-related macular degeneration [AMD].

Michael A. Klufas, MD, reviews the design and key findings from clinical trials for faricimab.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

Carl D. Regillo, MD, FACS; and David R. Lally, MD, discuss the recent FDA approval of faricimab and the potential impact of having a molecule that inhibits 2 pathways that play a role in diabetic macular edema and neovascularization in the treatment armamentarium.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the implications of real-world evidence indicating fewer visual gains associated with anti-VEGF therapies compared with clinical trials.

Dr Regillo leads a discussion with retina specialists about the utility and limitations of anti-VEGF agents in the treatment of patients with AMD and DME.

Dr Regillo, Dr Cooper, and Dr Klufas emphasize the importance of a personalized approach and share strategies for assessing outcomes in patients with AMD and DME.

A panel of retina specialists discuss how to balance durability, visual acuity, and other factors when selecting the appropriate regimen for patients with AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, share guidance on how to initiate conversations with patients who have been diagnosed with AMD or DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, review the clinical benefits of early detection of AMD and DME.

Carl D. Regillo, MD, FACS; Michael A. Klufas, MD; and David R. Lally, MD, discuss how increasing awareness regarding AMD and DME among patients and the medical community may lead to early treatment interventions.

However, initially observed eyes were found more at risk of developing moderate visual loss and more than 80% required treatment over 24 months.

The study shows fenofibrate use was associated with a lower risk of progression to PDR and VTDR, but not DME alone.

An increase in annual prevalence of beneficiaries with diabetes was observed in those who had ≥1 claim for DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%).

AGN-190584 showed superiority in efficacy over vehicle in mesopic DCNVA on day 30 with an acceptable safety profile for patients with presbyopia.

African American individuals and Hispanic individuals were more likely than non-Hispanic White individuals to report not being able to afford medications.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

New findings observing links between visual acuity, disease progression and risk loci could inform new clinical studies of the leading cause of irreversible vision loss.

Monthly IV pegcetacoplan was associated with 39% reduced risk of progression from incomplete to complete RPE and outer retinal atrophy.

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.